--- title: "QT Imaging posts strong Q1 growth amid ongoing losses" type: "News" locale: "en" url: "https://longbridge.com/en/news/286272682.md" description: "QT Imaging Holdings reported a 133% year-over-year revenue increase to $6.5 million in Q1 2026, driven by the shipment of Breast Acoustic CT scanners. Despite this growth, the company faced a net loss of $3.4 million and a decline in gross margin to 41%. Operational advancements include AMA approval for a new CPT code and FDA clearance for improved imaging. The company reaffirmed its 2026 revenue guidance of $39 million while facing ongoing investment needs. Analysts rate QTI stock as a Buy with a $10.00 price target, though concerns about financial performance persist." datetime: "2026-05-13T12:45:55.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286272682.md) - [en](https://longbridge.com/en/news/286272682.md) - [zh-HK](https://longbridge.com/zh-HK/news/286272682.md) --- # QT Imaging posts strong Q1 growth amid ongoing losses ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks An update from QT Imaging Holdings ( (QTI) ) is now available. On May 13, 2026, QT Imaging reported first-quarter 2026 revenue of $6.5 million, up 133% year over year, driven by the shipment of 13 Breast Acoustic CT scanners, though gross margin fell to 41% and the company posted a net loss of $3.4 million. Operating expenses rose as the company scaled commercialization and clinical activities, but net loss narrowed sharply due to lower nonrecurring financing charges, while cash and equivalents declined to $7.0 million at March 31. Operationally, QT Imaging secured AMA approval for a dedicated Category III CPT code effective January 2027, gained FDA 510(k) clearance for improved posterior breast imaging, and obtained UAE regulatory clearance tied to a multi-year distribution deal with minimum orders worth over $24 million. The company also launched new viewing and software tools, uplisted to Nasdaq, extended the maturity of its senior secured term loan to March 31, 2029 at a higher interest rate, and reaffirmed its 2026 revenue guidance of about $39 million, underscoring an aggressive growth strategy but continued investment needs for global adoption. The most recent analyst rating on (QTI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on QT Imaging Holdings stock, see the QTI Stock Forecast page. **Spark’s Take on QTI Stock** According to Spark, TipRanks’ AI Analyst, QTI is a Neutral. The score is held back primarily by weak financial performance (ongoing losses and cash burn despite improved equity) and limited valuation support (negative P/E, no dividend). These are partially offset by a constructive technical trend and positive corporate developments indicating accelerating commercialization and improved funding/liquidity. To see Spark’s full report on QTI stock, click here. **More about QT Imaging Holdings** QT Imaging Holdings, Inc., based in Novato, California, is a medical device company focused on transforming breast health management with its radiation-free, compression-free, 3D Breast Acoustic CT imaging systems and related software. The company targets the breast imaging market globally, partnering with distributors such as NXC Imaging in the U.S. and regional medical device distributors in the Gulf region to drive adoption of its QTscan platform and cloud-based services. **Average Trading Volume:** 39,661 **Technical Sentiment Signal:** Buy **Current Market Cap:** $91.4M For an in-depth examination of QTI stock, go to TipRanks’ Overview page. ### Related Stocks - [QTI.US](https://longbridge.com/en/quote/QTI.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [IHI.US](https://longbridge.com/en/quote/IHI.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [XHE.US](https://longbridge.com/en/quote/XHE.US.md) - [IHF.US](https://longbridge.com/en/quote/IHF.US.md) - [XHS.US](https://longbridge.com/en/quote/XHS.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [QTIH.US](https://longbridge.com/en/quote/QTIH.US.md) ## Related News & Research - [Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST](https://longbridge.com/en/news/286893528.md) - [Resona Asset Management Co. Ltd. Cuts Position in Danaher Corporation $DHR](https://longbridge.com/en/news/286897088.md) - [Neurothera Labs Announces Adoption of Semi-Annual Reporting](https://longbridge.com/en/news/287119698.md) - [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md) - [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)